Compare Mutual Funds
Risk
Very High
-
Rating
-
-
Min SIP Amount
₹500
-
Expense Ratio
2.61
-
NAV
₹9.30
-
Fund Started
09 Jun 2025
-
Fund Size
₹515.19 Cr
-
Exit Load
Exit Load for units in excess of 10% of the investment,1% will be charged for redemption within 1 year.
-
1 Year
-
-
3 Year
-
-
5 Year
-
-
Equity
95.92%
-
Cash
-0.44%
-
Top 10 Holdings
Sun Pharmaceutical Industries Ltd. | 10.23% |
Lupin Ltd. | 6.29% |
Abbott India Ltd. | 5.53% |
Torrent Pharmaceuticals Ltd. | 5.32% |
Ipca Laboratories Ltd. | 5.28% |
Laurus Labs Ltd. | 4.43% |
JB Chemicals & Pharmaceuticals Ltd. | 4.41% |
Astrazeneca Pharma India Ltd. | 3.92% |
SBI Life Insurance Company Ltd. | 3.45% |
Emcure Pharmaceuticals Ltd. | 3.36% |
-
Name
-
-
Start Date
-
-
Description
The scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns.
-
Launch Date
09 Jun 2025
-
